Limited direct value for Parkinson's therapeutic discovery, but the paper highlights sex/gender, hormonal, and psychosocial factors that are important to consider in neurodegeneration research, trial design, and understanding comorbid neuropsychiatric presentations.

Alerts clinicians to a rare, reversible thermoregulatory/autonomic complication of PD but provides minimal mechanistic or therapeutic information useful for Parkinson's drug discovery.

By aggregating human clinical and biomarker data, it helps prioritize inflammatory pathways and measurable biomarkers that could be targeted or used for patient stratification in PD therapeutic development.

Helps researchers navigate the neuroimaging–AI landscape to find datasets, methods, and collaborators for imaging-based biomarkers or diagnostic ML for Parkinson's, but offers little mechanistic or therapeutic actionable insight.

Useful for informing end‑of‑life care planning, service provision, and targeted palliative interventions but of limited direct value for Parkinson's therapeutic discovery because it lacks mechanistic, biomarker, or intervention development insights.

The study highlights dietary fatty acid composition, particularly DHA, as a potentially modifiable factor and prioritizes specific lipids for mechanistic, prospective, or interventional PD research, though causality remains unproven due to the cross-sectional design.

While the study is peripheral and not in a neurodegeneration model, detection of PD-linked chaperones (PARK7, HSP70) in bioactive EVs raises a plausible, but unproven, avenue for EV-mediated delivery of neuroprotective factors or modulation of proteostasis relevant to Parkinson's disease, meriting…

Low direct value for Parkinson's therapeutic discovery—although some premutation carriers exhibit parkinsonism, the review is descriptive and regional with no mechanistic insights, biomarkers, or intervention targets that would readily inform PD drug development.

Offers validated functional outcome measures that could inform endpoint selection in movement-disorder trials (including gait/fatigue assessments relevant to Parkinson's studies), but provides little direct mechanistic or therapeutic insight for PD drug discovery.

By connecting a Mendelian PD gene to endolysosomal/autophagy dysfunction and glial contributions, the paper identifies mechanistic pathways that are actionable for therapeutic targeting, biomarker development, and gene-based strategies.

VNS targets the gut–brain axis and inflammation—mechanisms relevant to PD that offer a minimally invasive, translational therapeutic approach—but the paper is a high-level review with limited PD-specific, actionable targets or experimental data.

Useful for improving symptomatic care, patient stratification, and awareness of autonomic dysfunction as a clinical feature in PD, but offers limited actionable insight for discovery of disease-modifying Parkinson's therapeutics.

By enabling fast, scalable, and accurate intraoperative identification of DBS target nuclei, this method can improve surgical targeting and efficiency—potentially enhancing clinical outcomes and facilitating wider deployment of DBS—though it does not directly inform molecular mechanisms or novel…

Identifies a reproducible subcortical imaging signature that could serve as a biomarker for early cognitive decline and trial enrichment in PD, but offers limited direct mechanistic or therapeutic leads for drug discovery.

Offers a valuable, well-characterized tissue and clinical dataset that can aid biomarker development and patient stratification for atypical parkinsonian syndromes, but provides limited direct mechanistic or therapeutic leads for classical alpha-synuclein Parkinson's disease.

While it offers important clinical guidance for diagnosis and referral, the paper provides minimal mechanistic or therapeutic insight for Parkinson's drug discovery, so its direct value to PD therapeutics is limited but relevant for clinical pathway optimization.

A blood-based tau measure that identifies Alzheimer co-pathology in LBD enables better patient stratification and longitudinal monitoring for clinical trials and practice, improving chances to test and target therapies in biologically defined subgroups even though it does not itself propose a…

Enhanced high-field imaging that yields clearer, faster, and safer visualization of subcortical targets has direct translational value for Parkinson's DBS planning and may improve surgical accuracy and outcomes, though it does not introduce new disease-modifying biology.

This identifies a noninvasive, readily obtainable biomarker for detecting and stratifying cognitive fluctuations in Lewy body disease, aiding diagnosis and clinical trial enrichment, though it offers limited direct mechanistic or therapeutic targets.

Offers clinical-level support for exercise as a non-pharmacological, potentially neuroprotective intervention relevant to PD symptoms and cognitive decline, but it provides limited actionable molecular targets or therapeutic-discovery insights.

Synthesizes preclinical evidence that exercise may modulate the central PD protein α-synuclein and support neuroprotection, offering mechanistic and translational hints for non‑pharmacological or adjunctive therapeutic strategies despite limited direct drug-discovery actionability.

Minimal direct value for Parkinson's therapeutic discovery, but important for clinical and research neuroimaging: it cautions that atypical cortical DAT-ligand uptake can reflect metastases or perfusion/BBB effects rather than synucleinopathy, which can prevent misdiagnosis and confounding in…

This paper has minimal direct relevance to Parkinson's therapeutic discovery—at best it offers a tangential observation about acute vagal modulation safety that could be of peripheral interest to neuromodulation approaches in PD but provides no mechanistic, biomarker, or therapeutic insights for…

For Parkinson's therapeutic discovery, the paper highlights a mechanistically plausible and druggable axis (calcium–cytoskeleton) with specific molecular components to prioritize for translational studies and biomarker work, though it is a conceptual review with limited PD-specific experimental or…

While offering limited mechanistic or therapeutic insight for drug discovery, the report is clinically relevant for PD research and development because it underscores the importance of monitoring autonomic/blood-pressure effects of disease and medications—information that informs safety…